While in the pre-clinical models, the BET inhibitors have displayed anti-cancer behavior broadly, the first-generation inhibitors have shown very average results clinically, most probably owing to the therapeutic index, which is quite narrow and does not include the ideal target engagement17,18. The gene discussed is DNER; the disease is cancer.